Form 4: Director Brian Gladden Receives RSU Grant at Dentsply Sirona

Director Brian T. Gladden was granted 22,822 restricted stock units in Dentsply Sirona Inc. as part of an equity compensation arrangement.

Summary

• Director Brian T. Gladden acquired 22,822 restricted stock units (RSUs) of Dentsply Sirona Inc. (XRAY) common stock.
• The transaction occurred on June 3, 2026, at a price of $0 per share, representing an equity grant.
• Following this transaction, the reporting person's total beneficial ownership increased to 51,863.522 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• The grant aligns the director's interests with long-term shareholder value through equity ownership.

Negatives

• None identified.

Risks

• The value of the granted RSUs is subject to market volatility and the future performance of Dentsply Sirona's common stock.

Future Outlook

The RSUs vest in full one year from the date of grant, June 3, 2026.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to ensure alignment between board members and shareholders in the medical technology and dental supply sector.

Comparison to Industry Standards

• The use of RSU grants as a component of director compensation is consistent with standard practices among S&P 500 and mid-cap healthcare companies.
• The one-year vesting schedule is a common retention and alignment mechanism for board members.

Stakeholder Impact

• Shareholders may view the increased equity stake of a director as a positive signal of confidence in the company's long-term prospects.

Next Steps

• The RSUs will vest on June 3, 2027.

Key Dates

Keywords

Dentsply Sirona, XRAY, Form 4, Insider Trading, Restricted Stock Units, Equity Compensation